Suffering from generic competition and patent losses, Eli Lilly & Co. froze salaries and cut bonuses last year--from the top management ranks on down. But the decreases in incentive pay didn't make a huge dent in those executive pay packages.
Baxter chief Robert Parkinson--who makes a perennial appearance on the list of the top-paid helmsman in biopharma--is in prime position to return this year, despite a drop in his overall compensation. But as for his colleagues gearing up to help biopharma spinoff Baxalta break free, they're in line for some pay bumps--assuming they stick around after the split. Read more >>
Johnson & Johnson has a Chinese strategy: long-term thinking. Despite an economic slowdown and regulatory crackdowns--and the example of other multinationals that have scaled back there--CEO Alex Gorsky figures it's worth it to ride out the storm. Read more >>
Jeremy Levin, known for his transformational efforts at Bristol-Myers Squibb and leadership stint at Teva Pharmaceuticals, has surfaced in the biotech world as chairman at Ovid Therapeutics, a startup working on rare neurological diseases with no treatments. Read more >>
POPULAR COMMENT THREADS
The #FierceMadness Sweet Sixteen saw no shortage of action this weekend. At the end of it all, we're left with just 8 drugs that still have a shot to bring home the glory--and plenty of questions about which it'll be. Read more from FiercePharmaMarketing >>
Industry watchers knew Medicare would be shelling out a whole lot more on hepatitis C treatments last year, thanks to new-and-improved drugs. But just how much more did it cough up?
Teva has been sitting on the sidelines for more than a year as its peers jumped head-first into a biopharma deal bonanza. But no longer: The Israeli company struck a $3.2 billion agreement to buy Auspex Pharmaceuticals, which will finally put it back onto the M&A map. And it's zeroing in on more deal targets, analysts say.
Talk about unintended consequences of a patent ruling. Pfizer's unprecedented effort to fight Lyrica copies in England has doctors and pharmacists squabbling, and the National Health Service stepping in to keep the peace.
Ireland-based Horizon Pharma snatched up Hyperion Therapeutics for $1.1 billion to get its hands on the company's rare disease meds, diversifying its portfolio and expanding its footprint in the orphan drug market.
For several years, Gilead Sciences CEO John Martin has collected annual compensation worth about $15 million and his stock gains since 2009 run into the hundreds of millions. But for a record-smashing year that vaulted his company into the ranks of the global top 10, Martin snared a comparatively small payoff in 2015.
From Our Sister Sites
Japan's Fujifilm, which snapped up a Texas vaccine manufacturer late last year, says it will pay more than $300 million for a Wisconsin company which has a platform for large-scale human cell production, including a kind of stem cells being used in some promising drug research.
A Sanofi Pasteur facility that was sidelined for more than two years after the FDA discovered mold problems is again producing the bladder cancer drug ImmuCyst/TheraCys, Sanofi's BCG vaccine for tuberculosis, which disappeared from the market after Sanofi shut the plant to do upgrades.